制藥網(wǎng)>產(chǎn)品庫>原料藥中間體、制劑>生物試劑>其它試劑>>Cisplatin試劑

Cisplatin試劑

參考價(jià)	￥420.00-￥1100.00

參考價(jià)

￥420.00-￥1100.00

具體成交價(jià)以合同協(xié)議為準(zhǔn)

公司名稱杭州昊鑫生物科技股份有限公司
品牌MCE
型號(hào)HY-17394
所在地杭州市
廠商性質(zhì)代理商
更新時(shí)間2023/5/22 14:03:33
訪問次數(shù)244

產(chǎn)品標(biāo)簽:

規(guī)格

100 mg	420.00元	10000 支可售
500 mg	1100.00元	10000 支可售

在線詢價(jià) 收藏產(chǎn)品查看電話同類產(chǎn)品

聯(lián)系我們時(shí)請(qǐng)說明是制藥網(wǎng) 上看到的信息，謝謝!

索取相關(guān)資料

公司介紹主營產(chǎn)品

杭州昊鑫生物科技股份有限公司成立于2009年初，是一家面向生命科學(xué)領(lǐng)域，從事科研機(jī)構(gòu)、高校、院所及生產(chǎn)企業(yè)所需科研試劑、耗材，儀器銷售和服務(wù)面向全國。

產(chǎn)品和服務(wù)涵蓋生命科學(xué)研究技術(shù)的諸多方面，提供覆蓋分子生物學(xué)、細(xì)胞生物學(xué)、植物學(xué)、生物化學(xué)、蛋白組學(xué)、免疫學(xué)等領(lǐng)域的實(shí)驗(yàn)產(chǎn)品以及生物技術(shù)服務(wù)等。目前一級(jí)代理品牌有：MCE（Medchemexpress）、Biochannel、AATbio、invivogen、Abnova、Atlas、Origene、Biovision、云克隆（Cloud-clone）、艾德萊(Aidlab)、Cayman、Jackson、Epigentek、Prospec、Sciencell、icellbioscience（賽百慷）、hkABCbio、chondrex、Mybiosource、Abbexa、Innovrsrch、HPI、Hitobiotec、Greerlabs，Ostex，4ADI，LDN等。

經(jīng)營理念：以誠信為本，保證產(chǎn)品質(zhì)量求生存，創(chuàng)造企業(yè)核心競(jìng)爭(zhēng)力求發(fā)展 , 堅(jiān)持用戶至上、服務(wù)至上的原則。

展開顯示更多內(nèi)容

胎牛血清、MCE抑制劑激動(dòng)劑、RNA提取試劑盒、ELISA試劑盒、重組蛋白

產(chǎn)品簡介在線詢價(jià)

產(chǎn)地	進(jìn)口	級(jí)別	其他

Cisplatin試劑是一種抗腫瘤的HL劑，它與 DNA 交聯(lián)引起癌細(xì)胞中 DNA 損傷。CDDP可激活鐵死亡 (ferroptosis) 并誘導(dǎo)自噬 (autophagy)。

Cisplatin試劑產(chǎn)品信息

生物活性

Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy^[1]^[2]^[3].

IC₅₀ & Target

DNA Alkylator/Crosslinker^[1]

體外研究
(In Vitro)

Cisplatin (CDDP) causes apoptosis of HeLa cells in a dose-dependent manner, with a concentration of 30 μM Cisplatin resulting in death of greater than 90% of the cell population by 24 h of treatment. The kinetics of Cisplatin-induced apoptosis are examined using a 30 μM concentration. Cisplatin Activates the MEK/ERK Signaling Pathway, 20 and 30 μM Cisplatin, both of which results in significant apoptosis, leads to strong activation of ERK^[1].
Cisplatin (50 μM) produces time-dependent apoptosis in renal proximal tubular cell (RPTCs), causing cell shrinkage, a 50-fold increase in caspase 3 activity, a 4-fold increase in phosphatidylserine externalization, and 5- and 15-fold increases in chromatin condensation and DNA hypoploidy, respectively^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

In melanoma-bearing mice, Cisplatin (CDDP; 4 mg/kg B.W.) reduces the size and weight of the solid tumors, and HemoHIM supplementation with Cisplatin enhances the decrease of both the tumor size and weight^[3].
Cisplatin administration results in significant increases in the kidney weight as a percentage of the total body weight, urine volume, serum creatinine, and blood urea nitrogen by about 132, 315, 797, and 556% in comparison with the control rats, respectively^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00098995	Peter MacCallum Cancer Centre, Australia\|National Cancer Institute (NCI)	Cervical Cancer	December 2004	Phase 1
NCT01616849	Sun Yat-sen University\|Fujian Cancer Hospital\|First People′s Hospital of Foshan\|People′s Hospital of Guangxi\|Guangxi Medical University\|Guangzhou Medical University\|Hubei Cancer Hospital\|Hunan Provincial Cancer Hospital\|Hangzhou Cancer Hospital\|Wuhan Union Hospital, China\|Tongji Hospital\|Jiangxi Provincial Cancer Hospital\|Affiliated Cancer Hospital of Shantou University Medical College\|Wuhan University\|Zhejiang Cancer Hospital	Stage IV Nasopharyngeal Carcinoma	May 2012	Phase 2
NCT01846390	Canadian Cancer Trials Group\|Celgene	Peripheral T-Cell Lymphoma\|Diffuse Large B-Cell Lymphoma	April 30, 2013	Phase 1

分子量

300.05

性狀

Solid

Formula

Cl₂H₆N₂Pt

CAS 號(hào)

15663-27-1

中文名稱

運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲(chǔ)存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性數(shù)據(jù)

In Vitro:

DMF : 5 mg/mL (16.66 mM; Need ultrasonic; DMSO can inactivate Cisplatin's activity)

H₂O : 1 mg/mL (3.33 mM; ultrasonic and warming and heat to 60°C; DMSO can inactivate Cisplatin's activity)

配制儲(chǔ)備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	3.3328 mL	16.6639 mL	33.3278 mL
5 mM	0.6666 mL	3.3328 mL	6.6656 mL
10 mM	0.3333 mL	1.6664 mL	3.3328 mL

請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 儲(chǔ)存時(shí)，請(qǐng)?jiān)?6 個(gè)月內(nèi)使用，-20°C 儲(chǔ)存時(shí)，請(qǐng)?jiān)?1 個(gè)月內(nèi)使用。

In Vivo:

請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥方式選擇適當(dāng)?shù)娜芙夥桨?。以下溶解方案都?qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：

——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；以下溶劑前顯示的百
分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

1.

請(qǐng)依序添加每種溶劑： 0.5% CMC-Na/saline water
Solubility: 20 mg/mL (66.66 mM); Suspended solution; Need ultrasonic
2.

請(qǐng)依序添加每種溶劑： 50% PEG300 50% saline
Solubility: 10 mg/mL (33.33 mM); Suspended solution; Need ultrasonic